Repligen completes acquisition of BioLife Solutions in cash-and-stock deal
RGEN•Repligen completed its acquisition of BioLife Solutions. BioLife holders received $11.25 per share in cash plus 0.1442 Repligen shares, and Repligen plans to outline the deal’s expected effect on its 2026 financial outlook on its Q3 2026 earnings call.
1. Deal terms
Repligen completed its acquisition of BioLife Solutions, expanding its cell and gene therapy tools footprint. BioLife holders received $11.25 per share in cash plus 0.1442 shares of Repligen stock. Repligen plans to outline the deal’s expected effect on its 2026 financial outlook on its Q3 2026 earnings call.
